University launches tender for next-generation sequencing reagents
A research university is setting up a flexible system to source sequencing chemistry, isolation kits and antibodies for an advanced medical materials project.
A research university is setting up a flexible system to source sequencing chemistry, isolation kits and antibodies for an advanced medical materials project.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
Univerzita Palackého v Olomouci has issued a tender for laboratory kits and reagents that will equip its teams for next-generation sequencing and protein analysis. The contract underpins the OP JAK ITI project on new materials in medical practice, tying advanced genomics directly to applied medical research. It signals strong demand for suppliers of sequencing chemistry, nucleic acid isolation kits and antibodies who can support a flexible, long-term research agenda.
On 8th April 2026, the university published a contract notice for the delivery of sequencing chemistry and related reagents for next-generation sequencing systems. The same procurement also covers kits for DNA and RNA isolation and antibodies for protein verification. Taken together, these elements span the full workflow from sample preparation, through sequencing, to confirmation of protein-level effects, giving the OP JAK ITI project a coherent technical backbone.
The inclusion of both DNA and RNA isolation reflects a need to study genomes and gene expression side by side. DNA kits support the characterisation of stable genetic changes, while RNA kits enable transcriptomic analysis that can change as cells respond to new materials or treatments. Antibodies for protein verification add a further layer, allowing researchers to validate whether observed genetic and transcriptional signals translate into changes at the protein level.
The focus on nucleic acids and proteins suggests the project will not stop at genetic characterisation but will also look at downstream biological effects, which is essential when assessing any innovation in medical practice. By investing in a broad set of reagents rather than a narrow panel, the university is building capacity for a range of studies that may evolve as the OP JAK ITI project progresses.
The tender establishes a dynamic purchasing system for the supply of kits and laboratory reagents. For laboratories relying on next-generation sequencing, consumption patterns can be hard to predict and chemistries change quickly as technology improves. A dynamic purchasing approach gives the contracting authority room to adapt product choices and volumes over time without restarting an entire procurement process each time needs shift.
In December 2025, a specialist hospital created a dynamic purchasing system for medical laboratory consumables, supplying kits, reagents and consumables for a medical genetics laboratory with periodic procurements based on specific needs over a 48‑month period. In April 2026, a multi-profile hospital launched a laboratory supplies and reagents system for a medical-diagnostic clinical laboratory, with quantities that may be adjusted and open participation for qualified candidates. And in December 2025, a national transport hospital introduced a dynamic purchasing system for laboratory reagents and consumables designed to adjust deliveries to actual needs.
These examples underline how dynamic purchasing systems in the health and research sectors are being used to keep participation open to qualified suppliers, to adjust specifications and quantities as requirements evolve, and to place orders at intervals that reflect real demand. The university’s system for sequencing chemistries and related kits fits neatly into this pattern, allowing new products to be taken into account and enabling competition at the level of individual call-offs while the overarching framework remains in place.
The move also sits alongside a broader shift towards dynamic purchasing across laboratories, hospitals and universities. In February 2026, Biomedicínske centrum Slovenskej akadémie vied set up a dynamic purchasing system for commonly available chemicals for laboratories, with potential environmental specifications. In November 2025, Nitrokémia Környezetvédelmi Tanácsadó és Szolgáltató Zrt. launched a dynamic purchasing system for additives and chemicals to support the operation of a water treatment system. And in March 2026, Plovdiv University went to market for laboratory reagents, consumables and glassware to support scientific and educational activities, with specific needs to be met through a dynamic purchasing mechanism.
Diagnostics is following a similar path. On 8th April 2026, HUS-yhtymä invited applications to a dynamic procurement system for PCR and nucleic acid diagnostics equipment, reagents and supplies, intended to support laboratory needs until August 2029. Across the hospital sector, a series of tenders – from pharmaceutical products for a national cardiology hospital to medicinal products for a healthcare provider – are being channelled through dynamic purchasing systems, some of which state that quantities will be requested as needed during the execution period.
Dynamic purchasing is not confined to laboratory and clinical consumables. In January 2026, Jihočeská univerzita v Českých Budějovicích set up a dynamic purchasing system for standard office ICT equipment and data servers, while the Zdravotnická záchranná služba Jihomoravského kraje launched a system for selected office ICT equipment and related services, with awards made at irregular intervals based on needs. The European Chemicals Agency (ECHA) in Helsinki is going further, using a dynamic purchasing system for IT services that spans project management, consulting, software development, cloud, cybersecurity and artificial intelligence.
For suppliers, the university’s sequencing-focused system sits at the intersection of several growth areas: next-generation sequencing chemistry, nucleic acid isolation and antibody-based protein verification. Providers that can demonstrate robust performance across these categories – or offer highly specialised products in one of them – are likely to find a receptive market as the OP JAK ITI project scales up its experimental work.
The pattern seen in other notices suggests how the system may operate in practice. A February 2026 tender for pharmaceuticals in Veliko Tarnovo sets out indicative quantities that may change and keeps access open to all qualified candidates. A February 2026 system for medicinal products in Sofia takes a similar approach, allowing for ongoing participation from qualified suppliers and adjustments to product specifications. That level of flexibility is well suited to research projects where the mix of target molecules, platforms and assays can shift as findings emerge.
For researchers, the procurement promises a more secure and responsive supply chain. Rather than relying on a single, fixed catalogue, scientists working under the OP JAK ITI project should benefit from access to a range of sequencing chemistries, isolation kits and antibodies that can be updated as new technologies become available. When aligned with potential environmental criteria seen in chemical-procurement systems such as the one at Biomedicínske centrum Slovenskej akadémie vied, dynamic purchasing can also help laboratories align scientific ambitions with sustainability goals.
With the contract notice published on 8th April 2026, the next steps will involve defining and running specific competitions under the dynamic purchasing system as the OP JAK ITI project develops. Experience from other laboratory and clinical systems – many of which run for several years and schedule procurements at irregular intervals based on need – points to a steady pipeline of call-offs rather than a single, one-off purchase.
Across Europe, universities, hospitals and research institutes are converging on dynamic purchasing as a way to secure recurring, innovation-sensitive supplies. The sequencing, isolation and antibody reagents sought by Univerzita Palackého v Olomouci form part of that pattern, and future notices in this area will be an important indicator of how research-intensive institutions are equipping themselves for the next wave of genomics-driven medicine.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.